Sarepta Therapeutics, Inc. (0L35.L)
USD 122.56
(-2.47%)
USD 122.56
(-2.47%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 1.39 Billion USD | -13.64% |
| 2022 | 1.61 Billion USD | 42.07% |
| 2021 | 1.13 Billion USD | 6.11% |
| 2020 | 1.07 Billion USD | 47.04% |
| 2019 | 729.62 Million USD | 73.49% |
| 2018 | 420.55 Million USD | -2.44% |
| 2017 | 431.05 Million USD | 2569.05% |
| 2016 | 16.15 Million USD | -30.98% |
| 2015 | 23.39 Million USD | 269.75% |
| 2014 | 6.32 Million USD | 279.38% |
| 2013 | 1.66 Million USD | -5.07% |
| 2012 | 1.75 Million USD | -4.61% |
| 2011 | 1.84 Million USD | -4.21% |
| 2010 | 1.92 Million USD | -3.9% |
| 2009 | 2 Million USD | -3.55% |
| 2008 | 2.07 Million USD | -3.13% |
| 2007 | 2.14 Million USD | 0.0% |
| 2006 | - USD | 0.0% |
| 2005 | - USD | 0.0% |
| 2004 | - USD | 0.0% |
| 2003 | - USD | 0.0% |
| 2002 | - USD | 0.0% |
| 2001 | - USD | 0.0% |
| 2000 | - USD | 0.0% |
| 1999 | - USD | 0.0% |
| 1998 | - USD | 0.0% |
| 1997 | - USD | 0.0% |
| 1996 | - USD | 0.0% |
| 1995 | - USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 1.37 Billion USD | -1.25% |
| 2024 Q2 | 1.36 Billion USD | -0.68% |
| 2023 Q1 | 1.28 Billion USD | -20.35% |
| 2023 FY | 1.39 Billion USD | -13.64% |
| 2023 Q4 | 1.39 Billion USD | 1.84% |
| 2023 Q3 | 1.37 Billion USD | 0.5% |
| 2023 Q2 | 1.36 Billion USD | 5.94% |
| 2022 Q2 | 1.14 Billion USD | 0.24% |
| 2022 Q3 | 1.57 Billion USD | 38.39% |
| 2022 Q4 | 1.61 Billion USD | 2.49% |
| 2022 FY | 1.61 Billion USD | 42.07% |
| 2022 Q1 | 1.13 Billion USD | -0.08% |
| 2021 Q4 | 1.13 Billion USD | -1.72% |
| 2021 Q1 | 1.15 Billion USD | 7.36% |
| 2021 Q2 | 1.15 Billion USD | 0.56% |
| 2021 Q3 | 1.15 Billion USD | 0.01% |
| 2021 FY | 1.13 Billion USD | 6.11% |
| 2020 Q3 | 768.69 Million USD | 0.28% |
| 2020 FY | 1.07 Billion USD | 47.04% |
| 2020 Q2 | 766.55 Million USD | 1.77% |
| 2020 Q4 | 1.07 Billion USD | 39.57% |
| 2020 Q1 | 753.21 Million USD | 3.23% |
| 2019 FY | 729.62 Million USD | 73.49% |
| 2019 Q2 | 481.24 Million USD | 0.7% |
| 2019 Q3 | 486.16 Million USD | 1.02% |
| 2019 Q4 | 729.62 Million USD | 50.08% |
| 2019 Q1 | 477.91 Million USD | 13.64% |
| 2018 FY | 420.55 Million USD | -2.44% |
| 2018 Q2 | 439.43 Million USD | 2.0% |
| 2018 Q1 | 430.81 Million USD | -0.06% |
| 2018 Q3 | 415.44 Million USD | -5.46% |
| 2018 Q4 | 420.55 Million USD | 1.23% |
| 2017 Q2 | 11.21 Million USD | -18.06% |
| 2017 Q1 | 13.68 Million USD | -15.24% |
| 2017 FY | 431.05 Million USD | 2569.05% |
| 2017 Q4 | 431.05 Million USD | 1277.95% |
| 2017 Q3 | 31.28 Million USD | 178.88% |
| 2016 Q1 | 20.97 Million USD | -10.35% |
| 2016 Q2 | 20.21 Million USD | -3.62% |
| 2016 Q3 | 18.59 Million USD | -8.01% |
| 2016 FY | 16.15 Million USD | -30.98% |
| 2016 Q4 | 16.15 Million USD | -13.16% |
| 2015 FY | 23.39 Million USD | 269.75% |
| 2015 Q3 | 23.28 Million USD | -9.25% |
| 2015 Q2 | 25.66 Million USD | 302.19% |
| 2015 Q1 | 6.38 Million USD | 0.82% |
| 2015 Q4 | 23.39 Million USD | 0.48% |
| 2014 FY | 6.32 Million USD | 279.38% |
| 2014 Q2 | 1.62 Million USD | -1.46% |
| 2014 Q3 | 6.27 Million USD | 287.11% |
| 2014 Q4 | 6.32 Million USD | 0.84% |
| 2014 Q1 | 1.64 Million USD | -1.38% |
| 2013 FY | 1.66 Million USD | -5.07% |
| 2013 Q3 | 1.69 Million USD | -1.29% |
| 2013 Q2 | 1.71 Million USD | -1.33% |
| 2013 Q1 | 1.73 Million USD | -1.25% |
| 2013 Q4 | 1.66 Million USD | -1.3% |
| 2012 Q4 | 1.75 Million USD | -1.18% |
| 2012 Q3 | 1.77 Million USD | -1.22% |
| 2012 Q2 | 1.8 Million USD | -1.15% |
| 2012 Q1 | 1.82 Million USD | -1.14% |
| 2012 FY | 1.75 Million USD | -4.61% |
| 2011 Q1 | 1.9 Million USD | -1.04% |
| 2011 Q2 | 1.88 Million USD | -1.05% |
| 2011 Q3 | 1.86 Million USD | -1.12% |
| 2011 Q4 | 1.84 Million USD | -1.07% |
| 2011 FY | 1.84 Million USD | -4.21% |
| 2010 Q1 | 3.08 Million USD | 54.37% |
| 2010 FY | 1.92 Million USD | -3.9% |
| 2010 Q3 | 1.94 Million USD | -0.97% |
| 2010 Q4 | 1.92 Million USD | -1.03% |
| 2010 Q2 | 1.96 Million USD | -36.48% |
| 2009 Q3 | 2.02 Million USD | -22.58% |
| 2009 Q4 | 2 Million USD | -1.23% |
| 2009 Q2 | 2.61 Million USD | 1.2% |
| 2009 Q1 | 2.58 Million USD | 24.65% |
| 2009 FY | 2 Million USD | -3.55% |
| 2008 Q2 | 2.1 Million USD | -0.83% |
| 2008 Q1 | 2.12 Million USD | -0.82% |
| 2008 Q4 | 2.07 Million USD | -0.68% |
| 2008 Q3 | 2.08 Million USD | -0.85% |
| 2008 FY | 2.07 Million USD | -3.13% |
| 2007 Q2 | 2.17 Million USD | 0.0% |
| 2007 Q4 | 2.14 Million USD | -0.8% |
| 2007 FY | 2.14 Million USD | 0.0% |
| 2007 Q1 | - USD | 0.0% |
| 2007 Q3 | 2.15 Million USD | -0.78% |
| 2006 Q4 | - USD | 0.0% |
| 2006 Q3 | - USD | 0.0% |
| 2006 Q1 | - USD | 0.0% |
| 2006 FY | - USD | 0.0% |
| 2006 Q2 | - USD | 0.0% |
| 2005 Q3 | - USD | 0.0% |
| 2005 Q1 | - USD | 0.0% |
| 2005 Q4 | - USD | 0.0% |
| 2005 FY | - USD | 0.0% |
| 2005 Q2 | - USD | 0.0% |
| 2004 Q4 | - USD | 0.0% |
| 2004 FY | - USD | 0.0% |
| 2004 Q2 | - USD | 0.0% |
| 2004 Q3 | - USD | 0.0% |
| 2004 Q1 | - USD | 0.0% |
| 2003 FY | - USD | 0.0% |
| 2003 Q4 | - USD | 0.0% |
| 2003 Q3 | - USD | 0.0% |
| 2003 Q2 | - USD | 0.0% |
| 2003 Q1 | - USD | 0.0% |
| 2002 Q2 | - USD | 0.0% |
| 2002 FY | - USD | 0.0% |
| 2002 Q1 | - USD | 0.0% |
| 2002 Q3 | - USD | 0.0% |
| 2002 Q4 | - USD | 0.0% |
| 2001 Q4 | - USD | 0.0% |
| 2001 Q1 | - USD | 0.0% |
| 2001 Q3 | - USD | 0.0% |
| 2001 Q2 | - USD | 0.0% |
| 2001 FY | - USD | 0.0% |
| 2000 Q1 | - USD | 0.0% |
| 2000 Q3 | - USD | 0.0% |
| 2000 Q2 | - USD | 0.0% |
| 2000 FY | - USD | 0.0% |
| 2000 Q4 | - USD | 0.0% |
| 1999 FY | - USD | 0.0% |
| 1999 Q1 | - USD | 0.0% |
| 1999 Q4 | - USD | 0.0% |
| 1999 Q2 | - USD | 0.0% |
| 1999 Q3 | - USD | 0.0% |
| 1998 Q2 | - USD | 0.0% |
| 1998 Q3 | - USD | 0.0% |
| 1998 FY | - USD | 0.0% |
| 1998 Q1 | - USD | 0.0% |
| 1998 Q4 | - USD | 0.0% |
| 1997 Q3 | - USD | 0.0% |
| 1997 Q2 | - USD | 0.0% |
| 1997 FY | - USD | 0.0% |
| 1997 Q1 | - USD | 0.0% |
| 1997 Q4 | - USD | 0.0% |
| 1996 FY | - USD | 0.0% |
| 1996 Q4 | - USD | 0.0% |
| 1995 FY | - USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Dynavax Technologies Corporation | 256.91 Million USD | -443.687% |
| Walgreens Boots Alliance, Inc. | 9.55 Billion USD | 85.38% |
| Supernus Pharmaceuticals, Inc. | 41.52 Million USD | -3263.614% |
| Perrigo Company plc | 4.07 Billion USD | 65.709% |
| Illumina, Inc. | 2.26 Billion USD | 38.249% |
| Thermo Fisher Scientific Inc. | 34.91 Billion USD | 96.0% |
| Iovance Biotherapeutics, Inc. | 1 Million USD | -139580.8% |
| IQVIA Holdings Inc. | 14.23 Billion USD | 90.185% |
| Heron Therapeutics, Inc. | 173.75 Million USD | -703.904% |
| Unity Biotechnology, Inc. | 26.99 Million USD | -5075.28% |
| Waters Corporation | 2.35 Billion USD | 40.7% |
| Biogen Inc. | 7.33 Billion USD | 80.965% |
| Sangamo Therapeutics, Inc. | 38.1 Million USD | -3565.778% |
| Evolus, Inc. | 126.54 Million USD | -1003.795% |
| Adicet Bio, Inc. | 17.7 Million USD | -7790.233% |
| Esperion Therapeutics, Inc. | 540.94 Million USD | -158.215% |
| FibroGen, Inc. | 170.45 Million USD | -719.459% |
| Agilent Technologies, Inc. | 2.73 Billion USD | 48.928% |
| Homology Medicines, Inc. | 44.05 Million USD | -3070.672% |
| Geron Corporation | 85.89 Million USD | -1526.105% |
| Alnylam Pharmaceuticals, Inc. | 2.39 Billion USD | 41.751% |
| Editas Medicine, Inc. | 36.53 Million USD | -3723.101% |
| Regeneron Pharmaceuticals, Inc. | 2.7 Billion USD | 48.322% |
| Amicus Therapeutics, Inc. | 445.05 Million USD | -213.848% |
| Cara Therapeutics, Inc. | 43.16 Million USD | -3135.824% |
| bluebird bio, Inc. | 330.32 Million USD | -322.857% |
| Myriad Genetics, Inc. | 145 Million USD | -863.316% |
| Corbus Pharmaceuticals Holdings, Inc. | 20.88 Million USD | -6588.338% |
| BioMarin Pharmaceutical Inc. | 1.13 Billion USD | -23.189% |
| Viking Therapeutics, Inc. | 1.26 Million USD | -110757.778% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| Intellia Therapeutics, Inc. | 115.34 Million USD | -1110.972% |
| Zoetis Inc. | 6.8 Billion USD | 79.468% |
| Abeona Therapeutics Inc. | 4.4 Million USD | -31631.213% |
| Mettler-Toledo International Inc. | 2.16 Billion USD | 35.565% |
| Atara Biotherapeutics, Inc. | 57.87 Million USD | -2313.616% |
| Vertex Pharmaceuticals Incorporated | 808.4 Million USD | -72.787% |
| Nektar Therapeutics | 230.4 Million USD | -506.251% |
| Axsome Therapeutics, Inc. | 186.37 Million USD | -649.473% |
| Aclaris Therapeutics, Inc. | 3.07 Million USD | -45339.427% |
| Kala Pharmaceuticals, Inc. | 36.32 Million USD | -3745.519% |
| Ionis Pharmaceuticals, Inc. | 1.45 Billion USD | 3.903% |
| Verastem, Inc. | 41.55 Million USD | -3261.186% |
| OPKO Health, Inc. | 326.56 Million USD | -327.729% |
| Exelixis, Inc. | 189.94 Million USD | -635.379% |
| Imunon, Inc. | 1.13 Million USD | -122503.053% |
| uniQure N.V. | 138.4 Million USD | -909.189% |
| Neurocrine Biosciences, Inc. | 428.4 Million USD | -226.052% |
| Corcept Therapeutics Incorporated | 151 Thousand USD | -924938.411% |
| Halozyme Therapeutics, Inc. | 1.49 Billion USD | 6.833% |
| Blueprint Medicines Corporation | 774.12 Million USD | -80.438% |
| Insmed Incorporated | 1.2 Billion USD | -16.015% |
| Agios Pharmaceuticals, Inc. | 56.98 Million USD | -2351.056% |
| TG Therapeutics, Inc. | 110.79 Million USD | -1160.714% |
| Incyte Corporation | 38.28 Million USD | -3548.257% |
| Emergent BioSolutions Inc. | 877.5 Million USD | -59.18% |